Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Annals of the American Thoracic Society · 2025
DOI: 10.1513/annalsats.202407-736oc ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the American Thoracic Society, 2025. Verfasst von Christopher N Schmickl und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology and. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Venlafaxine Hydrochloride, Acetazolamide, Eszopiclone. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, American Heart Association-American Stroke Association.
Abstract (Originalsprache)
Rationale
Acetazolamide, eszopiclone, and venlafaxine may target different underlying mechanisms of obstructive sleep apnea (OSA) and individually may partially reduce OSA severity in select patients. We tested whether acetazolamide plus eszopiclone (DualRx) reduces OSA severity. We further explored whether the addition of venlafaxine (TripleRx) alleviates OSA in patients who do not fully respond to DualRx.
Methods
In this double-blind crossover trial, 20 patients with OSA underwent baseline polysomnography followed by DualRx/placebo phases in random order. Subsequently, 18 patients underwent an open-label TripleRx phase. Each phase lasted 3 days and concluded with polysomnography. The primary outcome was the placebo-adjusted change in apnea–hypopnea index during supine, non–rapid eye movement sleep (AHINREM,supine) from baseline to DualRx. Secondary outcomes included other OSA metrics, sleep parameters, and select clinical outcomes (blood pressure, symptoms, and vigilance).
Results
Participants were on average middle aged, overweight, and relatively diverse (20% women, 60% non-White), with severe OSA (median [interquartile range] AHINREM,supine, 32.8 [20 to 48.8] events/h). Compared with placebo, DualRx was well tolerated and improved AHINREM,supine (−13.8 [−24.1 to −5.2] events/h or −45% [−77% to −14%]; P Wilcoxon = 0.003), overall AHI, hypoxic burden, and sleep architecture (P < 0.05) but not the selected clinical outcomes. TripleRx did not provide a clear benefit relative to DualRx, although some measures of OSA-related hypoxemia improved more substantially. There were no serious side effects.
Conclusions
Short-term use of dual-drug therapy with DualRx substantially reduced OSA severity. Adding venlafaxine did not generally reduce OSA severity but may be beneficial for some patients. Longer term studies are needed to assess effects on clinically important outcomes. Clinical trial registered with www.clinicaltrials.gov (NCT04639193).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology and.
- Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Bioengineering, University of California, San Diego, San Diego, California; and.
ORCID-Profile: Christopher N Schmickl, Scott A Sands
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- American Heart Association-American Stroke Association
- NIA NIH HHS
- American Heart Association
- American Thoracic Society
- AASMF
- National Heart, Lung, and Blood Institute
Zitieren
APA
Schmickl, C. N., Orr, J. E., Alex, R. M., Gruenberg, E., Parra, G., White, S., Spenceley, A., DeSarkar, T., Kong, M., DeYoung, P. N., Sands, S. A., Owens, R. L., & Malhotra, A. (2025). Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202407-736oc
Vancouver
Schmickl CN, Orr JE, Alex RM, Gruenberg E, Parra G, White S, et al. Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Annals of the American Thoracic Society. 2025. doi:10.1513/annalsats.202407-736oc
BibTeX
@article{Schmickl2025,
author = {Schmickl, Christopher N and Orr, Jeremy E and Alex, Raichel M and Gruenberg, Eli and Parra, Gabriela and White, Stephanie and Spenceley, Alex and DeSarkar, Tia and Kong, Mitchell and DeYoung, Pamela N and Sands, Scott A and Owens, Robert L and Malhotra, Atul},
title = {Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial},
journal = {Annals of the American Thoracic Society},
year = {2025},
doi = {10.1513/annalsats.202407-736oc}
}
EUVIMED